Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Market Closed 10-23 16:00:00 EDT

26.87

-1.36

-4.82%

盘后26.87

+0.000.00%

19:30 EDT

High28.33	Low26.73	Vol377.55K
Open28.00	D1 Closing28.23	Amplitude5.67%
Mkt Cap1.75B	Tradable Cap1.21B	Total Shares65.18M
T/O10.20M	T/O Rate0.84%	Tradable Shares45.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":26.87,"timestamp":1792785600000,"preClose":28.23,"halted":0,"volume":377549,"hourTrading":{"tag":"盘后","latestPrice":26.87,"preClose":26.87,"latestTime":"19:30 EDT","volume":64119,"amount":1722877.53,"timestamp":1792798204791,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.048175699610343584,"floatShares":45024692,"shares":65176700,"eps":-9.052203,"marketStatus":"Market Closed","change":-1.36,"latestTime":"10-23 16:00:00 EDT","open":28,"high":28.33,"low":26.73,"amount":10200177.14967,"amplitude":0.056677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":28.23,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.95,"preClose":28.23,"latestTime":"09:27 EDT","volume":48,"amount":1386.6,"timestamp":1792762040010,"change":0.72,"changeRate":0.025505,"amplitude":0.005668},"postHourTrading":{"tag":"盘后","latestPrice":26.87,"preClose":26.87,"latestTime":"19:30 EDT","volume":64119,"amount":1722877.53,"timestamp":1792798204791,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6748306705592857,"impliedVol":0.7362,"impliedVolPercentile":0.2908},"requestUrl":"/m/hq/s/ZBIO/wiki","defaultTab":"wiki","newsList":[{"id":"2676546255","title":"Learn Why The Bull Case For Zenas BioPharma Stock Could Change Following Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2676546255","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676546255?lang=en_us&edition=fundamental","pubTime":"2026-10-17 14:26","pubTimestamp":1792218378,"startTime":"0","endTime":"0","summary":"Zenas BioPharma reported new Phase 3 INDIGO data in IgG4-related disease, with obexelimab showing high 12 month flare free probabilities, low glucocorticoid rescue use, and adverse event rates comparable to or lower than in the randomized period.\nThe firm also highlighted reduced glucocorticoid toxicity and preserved vaccine related immunity after long term obexelimab exposure, which speaks directly to treatment burden and long run care costs in autoimmune disease management.\nWe will now...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/learn-why-the-bull-case-for-zenas-biopharma-stock-could-chan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676951149","title":"Zenas BioPharma Grants 74,900 Restricted Stock Units to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2676951149","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676951149?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:15","pubTimestamp":1792181716,"startTime":"0","endTime":"0","summary":"Zenas BioPharma grants 74,900 restricted stock units to new employeesZenas BioPharma granted 74,900 restricted stock units to newly hired employees on October 15, 2026.The awards fall under the 2026 I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nNDL83gmT9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BQXX3C00.GBP","BK4112","SG9999014005.SGD","BCDF","LU2210149790.SGD","BK4588","SG9999014039.USD","BK4585","IE00BQXX3D17.EUR","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","ZBIO","LU0314104364.USD","IE00BQXX3F31.USD","NDAQ","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4139","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676511489","title":"Zenas Biopharma Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676511489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676511489?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:15","pubTimestamp":1792181700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nTUA1FWGPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676514832","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676514832","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676514832?lang=en_us&edition=fundamental","pubTime":"2026-10-17 04:15","pubTimestamp":1792181700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/16/3382791/0/en/zenas-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675035093","title":"Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675035093","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675035093?lang=en_us&edition=fundamental","pubTime":"2026-10-13 21:55","pubTimestamp":1791899713,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $45.00. The word on The Street in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675559543","title":"Zenas BioPharma Price Target Maintained with a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2675559543","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675559543?lang=en_us&edition=fundamental","pubTime":"2026-10-13 18:44","pubTimestamp":1791888240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675138847","title":"Zenas Pharma: Obexelimab Data Reinforce Buy/High-Risk View with Unchanged $48 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2675138847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675138847?lang=en_us&edition=fundamental","pubTime":"2026-10-13 05:58","pubTimestamp":1791842322,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz has maintained their bullish stance on ZBIO stock, giving a Buy rating on September 30. Yigal Nochomovitz has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/zenas-pharma-obexelimab-data-reinforce-buy-high-risk-view-with-unchanged-48-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/zenas-pharma-obexelimab-data-reinforce-buy-high-risk-view-with-unchanged-48-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674807874","title":"Zenas BioPharma Says Phase 3 Indigo Extension Shows 0.93 12-Month Flare-Free Probability for Obexelimab in IgG4-RD","url":"https://stock-news.laohu8.com/highlight/detail?id=2674807874","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674807874?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802851,"startTime":"0","endTime":"0","summary":"Zenas BioPharma says Phase 3 INDIGO extension shows 0.93 12-month flare-free probability for obexelimab in IgG4-RDZenas Biopharma disclosed new Phase 3 INDIGO open-label extension results for obexelim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL6NdkGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210150020.SGD","BK4112","SG9999014021.USD","IE00BN0W2W23.USD","ZBIO","IE00BN0W2V16.EUR","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","IE00BQXX3D17.EUR","BCDF","LU2210149790.SGD","BK4139","BK4585","BK4588","IE00BQXX3F31.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00BQXX3C00.GBP","LU2095319765.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674742588","title":"Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2674742588","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674742588?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802800,"startTime":"0","endTime":"0","summary":"– Phase 3 INDIGO open-label extension findings demonstrated sustained clinical activity of obexelimab – – Additional analyses of secondary endpoints showed that significantly fewer patients experience","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/12/3378786/0/en/zenas-biopharma-announces-the-presentation-of-new-obexelimab-data-in-igg4-related-disease-at-the-6th-international-symposium-on-igg4-related-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","BK4139","ZBIO","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673097313","title":"Zenas BioPharma Outlines Monarch Phase 3 Trial Design for Orelabrutinib in Non-Active Secondary Progressive MS","url":"https://stock-news.laohu8.com/highlight/detail?id=2673097313","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673097313?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:05","pubTimestamp":1791371132,"startTime":"0","endTime":"0","summary":"Zenas BioPharma outlines Monarch Phase 3 trial design for orelabrutinib in non-active secondary progressive MSZenas BioPharma flagged seven posters for MSToronto2026 on Oct. 21-23, 2026, outlining ore","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL2Bj9nR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BQXX3C00.GBP","BK4139","IE00BN0W2W23.USD","BK4112","BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","SG9999014005.SGD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","IE00BN0W2T93.GBP","ZBIO","SG9999014039.USD","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673209736","title":"Zenas Biopharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at Mstoronto2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673209736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673209736?lang=en_us&edition=fundamental","pubTime":"2026-10-07 19:05","pubTimestamp":1791371100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nTUABCLKKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673405374","title":"Zenas BioPharma to Host Virtual R&D Event on Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2673405374","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673405374?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:05","pubTimestamp":1791284725,"startTime":"0","endTime":"0","summary":"Zenas BioPharma to host virtual R&D event on pipeline updatesZenas BioPharma will host a virtual R&D event on Oct. 27, 2026, from 8:00 a.m. to 9:30 a.m. ET.Management will outline the R&D pipeline, wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL7l0yXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","SG9999014005.SGD","SG9999014013.SGD","BCDF","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","IE00BQXX3F31.USD","IE00BN0W2W23.USD","BK4585","IE00BGHQF748.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","ZBIO","BK4139","IE00BQXX3D17.EUR","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","BK4112","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671785969","title":"Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2671785969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671785969?lang=en_us&edition=fundamental","pubTime":"2026-09-30 23:33","pubTimestamp":1790782431,"startTime":"0","endTime":"0","summary":"Zenas BioPharma's  investor update supports a larger addressable market for obexelimab in immunoglobulin G4-related disease, with room for market penetration and potential safety differentiation, Wedbush said in a Wednesday note.Zenas increased its estimate to about 30,000 to 40,000 prevalent US IgG4-related disease cases, including about 25,000 diagnosed and treated patients, and now estimates a roughly $4 billion commercial opportunity in the US, the firm noted. Wedbush attributed the increase to improved diagnosis.The firm noted Zenas' estimate that Uplizna, the only approved competitor, has reached about 1,200 unique patients 16 months after launch.The firm said the data and physician feedback support an opportunity for advanced treatments beyond as-needed glucocorticoids, with significant unmet need remaining.Wedbush reiterated its outperform rating and $45 price target.Price: 28.29, Change: +1.53, Percent Change: +5.72","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671519788","title":"Zenas BioPharma price target raised to $48 from $41 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2671519788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671519788?lang=en_us&edition=fundamental","pubTime":"2026-09-30 22:10","pubTimestamp":1790777428,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Zenas BioPharma (ZBIO) to $48 from $41 and keeps a Buy rating on the shares after updating the firm’s obexel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-raised-to-48-from-41-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-raised-to-48-from-41-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671055207","title":"Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671055207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671055207?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:25","pubTimestamp":1790774749,"startTime":"0","endTime":"0","summary":"In a report released today, from Wedbush maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $45.00. Zenas BioPharma, Inc. has...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671053262","title":"Zenas BioPharma Price Target Maintained with a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2671053262","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671053262?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:39","pubTimestamp":1790764740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146176","title":"Zenas BioPharma to Present Phase 3 Indigo Open-Label Extension Data on Obexelimab in IgG4-Related Disease at IgG4ward Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146176?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075117,"startTime":"0","endTime":"0","summary":"Zenas BioPharma to present Phase 3 INDIGO open-label extension data on obexelimab in IgG4-related disease at IgG4ward symposiumZenas Biopharma scheduled new Phase 3 INDIGO obexelimab updates in IgG4-r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL5ZTZ5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014021.USD","NDAQ","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","BCDF","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","BK4585","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146119","title":"Zenas Biopharma Announces Upcoming Presentations of Obexelimab Data in Igg4-Related Disease at the Igg4ward! 6TH International Symposium on Igg4-Related Disease and Acr Convergence 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146119?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA9MFYDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167073","title":"H.C. Wainwright Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167073","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167073?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:57","pubTimestamp":1790013438,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Caufield from H.C. Wainwright maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $44.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668973382","title":"Zenas BioPharma Grants Inducement Awards of 53,700 Stock Options, 98,900 RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2668973382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668973382?lang=en_us&edition=fundamental","pubTime":"2026-09-19 04:15","pubTimestamp":1789762518,"startTime":"0","endTime":"0","summary":"Zenas BioPharma grants inducement awards of 53,700 stock options, 98,900 RSUs to new hiresZenas BioPharma set inducement awards dated Sept. 15, 2026 for newly hired employees: stock options for 53,700","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL6kFgK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","SG9999014005.SGD","BCDF","IE00BQXX3C00.GBP","ZBIO","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU2095319765.USD","NDAQ","IE00BQXX3F31.USD","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","BK4139","BK4585","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":0.0817},{"period":"1month","weight":-0.0931},{"period":"3month","weight":-0.1158},{"period":"6month","weight":0.4772},{"period":"1year","weight":0.0744},{"period":"ytd","weight":-0.26}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}